Biotechnology company Genzyme intends to get rid of its genetics and diagnostics units in order to improve shareholder value. The Cambridge, Massachusetts-based company said it has identified “some potential strategic partners” for the businesses as part of a plan to create near-term ...
Please Login to read the full article.
